Tafamidis, a TTR stabilizer that attenuates TTR dissociation and thereby slows amyloid fibril formation, was recently shown to reduce mortality and cardiac hospitalizations in patients with symptomatic HF with ATTR-CM.13 This evidence concerns the gene TTR and hydrops fetalis.